Teijin buys somavaratan rights from Versartis in estimated $140 million deal

10 August 2016
mergers-acquisitions-big

Japanese drugmaker Teijin Pharma (TYO: 3401) has bought the rights to develop and commercialize somavaratan (VRS-317), a potential long-acting form of recombinant growth hormone (rhGH), in Japan.

Teijin has paid USA-based Versartis (Nasdaq: VSAR), an endocrine-focused biopharma which is developing somavaratan for the treatment of growth hormone deficiency (GHD), $40 million in an upfront payment and could pay $100 million more in potential development, regulatory and sales milestones.

It estimates the market size of the existing growth hormone products in Japan for pediatric GHD at $580 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology